Hubei Guangji Pharmaceutical Co Ltd
SZSE:000952
Hubei Guangji Pharmaceutical Co Ltd
SZSE:000952
Price:
7.01
CNY
-0.28%
Market Closed
Market Cap:
¥2.4B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Hubei Guangji Pharmaceutical Co Ltd
SZSE:000952
|
CN |
|
Grupo Pochteca SAB de CV
BMV:POCHTECB
|
MX |
|
A
|
Arem Pacific Corp
OTC:ARPC
|
AU |
|
Aroa Biosurgery Ltd
ASX:ARX
|
NZ |
|
G
|
Garda Diversified Property Fund
ASX:GDF
|
AU |
|
Benchmark Electronics Inc
NYSE:BHE
|
US |
|
A
|
Anhui Wanwei Updated High-tech Material Industry Co Ltd
SSE:600063
|
CN |
|
W
|
Waterdrop Inc
NYSE:WDH
|
CN |
|
Atlantic American Corp
NASDAQ:AAME
|
US |
|
T
|
TeamViewer SE
F:TMV1
|
DE |
|
E
|
E-Data Teknoloji Pazarlama AS
IST:EDATA.E
|
TR |
|
Eolus Vind AB (publ)
STO:EOLU B
|
SE |
|
S
|
SRIVARU Holding Ltd
NASDAQ:SVMH
|
KY |
|
TCI Express Ltd
NSE:TCIEXP
|
IN |
|
TTK Prestige Ltd
NSE:TTKPRESTIG
|
IN |
|
Lazydays Holdings Inc
F:5ZL
|
US |
Multiples-Based Value
The
Multiples-Based Value for
Hubei Guangji Pharmaceutical Co Ltd (000952)
under the Base Case is
hidden
CNY.
Compared with the current market price of 7.01 CNY, the stock appears
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Hubei Guangji Pharmaceutical Co Ltd Multiples-Based Value
LOCKED
Multiples Across Competitors
Competitors Multiples
Hubei Guangji Pharmaceutical Co Ltd Competitors
Hubei Guangji Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Hubei Guangji Pharmaceutical Co Ltd
SZSE:000952
|
2.5B CNY | 4 | -10.5 | -16.4 | -16.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
887.6B USD | 13.6 | 43 | 29 | 31 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.2B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236.2B GBP | 5.3 | 30.6 | 16.9 | 23.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.5 | 11.6 | 13 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
300.5B USD | 4.6 | 16.5 | 10.2 | 12.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
234.4B CHF | 5.2 | 20.8 | 12.9 | 16.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.1B USD | 2.4 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118B USD | 2.5 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
